| Literature DB >> 28903750 |
Hanna E Tervonen1,2, Sanchia Aranda3,4, David Roder5,3, Hui You3, Richard Walton3, Stephen Morrell3,6, Deborah Baker3, David C Currow3.
Abstract
BACKGROUND: Public concerns are commonly expressed about widening health gaps. This cohort study examines variations and trends in cancer survival by socio-economic disadvantage, geographical remoteness and country of birth in an Australian population over a 30-year period.Entities:
Keywords: Australia; Cultural diversity; Neoplasms; Rural population; Socioeconomic factors; Survival analysis
Mesh:
Year: 2017 PMID: 28903750 PMCID: PMC5598077 DOI: 10.1186/s12889-017-4692-y
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Characteristics of the study population overall and by remoteness, socio-economic disadvantage and country of birth category, NSW 1980–2008
| All | Remoteness | SEIFA quintile | Country of birth | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Major cities | Inner regional | Outer regional/Remote | 1 | 2 | 3 | 4 | 5 | Australia | Other English | Non-English | Unknown | ||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| n (%)b | n (%)b | n (%)b | n (%)b | n (%)b | n (%)b | n (%)b | n (%)b | n (%)b | n (%)b | n (%)b | n (%)b | n (%)b | |
| Sex | |||||||||||||
| Male | 358,011 (55.0) | 247,353 (54.0) | 80,894 (57.0) | 29,764 (58.4) | 60,849 (52.8) | 63,987 (54.2) | 71,964 (55.3) | 80,415 (56.2) | 80,796 (55.9) | 242,324 (54.5) | 38,771 (56.2) | 51,566 (55.4) | 25,350 (57.1) |
| Female | 293,234 (45.0) | 211,102 (46.1) | 60,937 (43.0) | 21,195 (41.6) | 54,503 (47.3) | 54,035 (45.8) | 58,147 (44.7) | 62,811 (43.9) | 63,738 (44.1) | 202,555 (45.5) | 30,173 (43.8) | 41,476 (44.6) | 19,030 (42.9) |
| Agea | |||||||||||||
| < 65 | 281,795 (43.3) | 201,289 (43.9) | 58,658 (41.4) | 21,848 (42.9) | 56,631 (49.1) | 53,899 (45.7) | 55,758 (42.9) | 57,772 (40.3) | 57,735 (40.0) | 186,292 (41.9) | 26,599 (38.6) | 43,847 (47.1) | 25,057 (56.5) |
| 65–79 | 272,415 (41.8) | 188,097 (41.0) | 62,278 (43.9) | 22,040 (43.3) | 42,786 (37.1) | 46,918 (39.8) | 54,767 (42.1) | 63,333 (44.2) | 64,611 (44.7) | 190,277 (42.8) | 29,354 (42.6) | 38,084 (40.9) | 14,700 (33.2) |
| ≥ 80 | 96,987 (14.9) | 69,032 (15.1) | 20,889 (14.7) | 7066 (13.9) | 15,923 (13.8) | 17,197 (14.6) | 19,582 (15.1) | 22,112 (15.4) | 22,173 (15.3) | 68,308 (15.4) | 12,990 (18.8) | 11,110 (11.9) | 4579 (10.3) |
| Summary stage | |||||||||||||
| Localised | 281,783 (43.3) | 200,462 (43.7) | 60,520 (42.7) | 20,801 (40.8) | 56,004 (48.6) | 53,486 (45.3) | 56,010 (43.1) | 59,226 (41.4) | 57,057 (39.5) | 190,129 (42.7) | 27,706 (40.2) | 36,426 (39.2) | 27,522 (62.0) |
| Regional | 135,648 (20.8) | 97,486 (21.3) | 27,858 (19.6) | 10,304 (20.2) | 24,823 (21.5) | 24,529 (20.8) | 26,788 (20.6) | 29,332 (20.5) | 30,176 (20.9) | 95,211 (21.4) | 15,094 (21.9) | 22,190 (23.9) | 3153 (7.1) |
| Distant | 107,067 (16.4) | 76,682 (16.7) | 22,079 (15.6) | 8306 (16.3) | 16,109 (14.0) | 18,464 (15.6) | 21,406 (16.5) | 24,635 (17.2) | 26,453 (18.3) | 75,315 (16.9) | 12,852 (18.6) | 17,453 (18.8) | 1447 (3.3) |
| Unknown | 126,747 (19.5) | 83,825 (18.3) | 31,374 (22.1) | 11,548 (22.7) | 18,416 (16.0) | 21,543 (18.3) | 25,907 (19.9) | 30,033 (21.0) | 30,848 (21.3) | 84,224 (18.9) | 13,292 (19.3) | 16,973 (18.2) | 12,258 (27.6) |
| Diagnostic period | |||||||||||||
| 1980–89 | 157,443 (24.2) | 116,766 (25.5) | 29,073 (20.5) | 11,604 (22.8) | 24,896 (21.6) | 28,523 (24.2) | 33,320 (25.6) | 36,070 (25.2) | 34,634 (24.0) | 115,238 (25.9) | 19,539 (28.3) | 17,418 (18.7) | 5248 (11.8) |
| 1990–99 | 229,566 (35.3) | 162,827 (35.5) | 49,447 (34.9) | 17,292 (33.9) | 41,457 (35.9) | 40,943 (34.7) | 45,402 (34.9) | 50,154 (35.0) | 51,610 (35.7) | 159,513 (35.9) | 24,196 (35.1) | 32,311 (34.7) | 13,546 (30.5) |
| 2000–08 | 264,236 (40.6) | 178,862 (39.0) | 63,311 (44.6) | 22,063 (43.3) | 48,999 (42.5) | 48,556 (41.1) | 51,389 (39.5) | 57,002 (39.8) | 58,290 (40.3) | 170,128 (38.2) | 25,209 (36.6) | 43,313 (46.6) | 25,586 (57.7) |
| Status | |||||||||||||
| Alive | 271,757 (41.7) | 189,946 (41.4) | 61,046 (43.0) | 20,765 (40.8) | 58,419 (50.6) | 53,105 (45.0) | 52,976 (40.7) | 54,900 (38.3) | 52,357 (36.2) | 168,015 (37.8) | 23,787 (34.5) | 41,228 (44.3) | 38,727 (87.3) |
| Died (cancer)c | 259,616 (39.9) | 183,671 (40.1) | 54,966 (38.8) | 20,979 (41.2) | 38,846 (33.7) | 44,072 (37.3) | 52,338 (40.2) | 60,307 (42.1) | 64,053 (44.3) | 186,802 (42.0) | 31,730 (46.0) | 38,703 (41.6) | 2381 (5.4) |
| Died (other cause) | 119,872 (18.4) | 84,838 (18.5) | 25,819 (18.2) | 9215 (18.1) | 18,087 (15.7) | 20,845 (17.7) | 24,797 (19.1) | 28,019 (19.6) | 28,124 (19.5) | 90,062 (20.2) | 13,427 (19.5) | 13,111 (14.1) | 3272 (7.4) |
SEIFA Socio-Economic Index for Areas (1: least disadvantaged – 5: most disadvantaged quintile); Country of birth categorised into Australia, other English-speaking and non-English speaking countries and unknown
aAge at diagnosis missing for 48 cases throughout 1980–2008. bColumn percentages (due to rounding all percentages do not add up to 100%). cDied due to the cancer of diagnosis
Competing risk regression models of risk of cancer death, by remoteness, socio-economic disadvantage and country of birth category, NSW 1980–2008
| Unadjusted | Model 1a | Model 2b | Model 3b | |
|---|---|---|---|---|
| Remoteness | SHR (95% CI) | SHR (95% CI) | SHR (95% CI) | SHR (95% CI) |
| Major cities | 1 | 1 | 1 | 1 |
| Inner regional | 0.98 (0.97–0.99) | 0.97 (0.96–0.98) | 1.01 (1.00–1.02) | 1.01 (1.00–1.02) |
| Outer regional/ Remote | 1.06 (1.04–1.07) | 1.02 (1.01–1.04) | 1.04 (1.03–1.06) | 1.05 (1.03–1.06) |
| SEIFA quintile | ||||
| 1 (least disadvantaged) | 1 | 1 | 1 | 1 |
| 2 | 1.14 (1.13–1.16) | 1.11 (1.10–1.13) | 1.05 (1.04–1.07) | 1.04 (1.02–1.06) |
| 3 | 1.26 (1.24–1.28) | 1.19 (1.18–1.21) | 1.09 (1.07–1.10) | 1.08 (1.06–1.09) |
| 4 | 1.35 (1.33–1.36) | 1.26 (1.25–1.28) | 1.12 (1.11–1.14) | 1.11 (1.09–1.12) |
| 5 (most disadvantaged) | 1.46 (1.44–1.47) | 1.37 (1.35–1.39) | 1.17 (1.16–1.19) | 1.15 (1.13–1.17) |
| Country of birth | ||||
| Australia | 1 | 1 | 1 | 1 |
| Other English speaking | 1.14 (1.12–1.15) | 1.10 (1.08–1.10) | 1.00 (1.00–1.02) | 0.99 (0.98–1.01) |
| Non-English speaking | 1.01 (1.00–1.03) | 1.09 (1.08–1.10) | 0.93 (0.92–0.94) | 0.91 (0.90–0.92) |
| Unknown | 0.11 (0.11–0.11) | 0.14 (0.13–0.14) | 0.20 (0.19–0.21) | 0.23 (0.22–0.24) |
SEIFA Socio-Economic Index for Areas, SHR Sub-hazard ratio, CI Confidence interval; Country of birth categorised into Australia, other English-speaking and non-English speaking countries and unknown
aModel 1 adjusted for sex, age, diagnostic period and, as appropriate, for remoteness/SEIFA quintile/country of birth
bModel 2 further adjusted for cancer site and Model 3 further adjusted for summary stage
Competing risk regression models of risk of cancer death by remoteness, socio-economic disadvantage and country of birth category, stratified by diagnostic period (1980–1989, 1990–1999, 2000–2008), NSW 1980–2008
| 1980–1989 | 1990–1999 | 2000–2008 | ||||
|---|---|---|---|---|---|---|
| Site-adjusteda | Stage-adjustedb | Site-adjusteda | Stage-adjustedb | Site-adjusteda | Stage-adjustedb | |
| Remoteness | SHR (95% CI) | SHR (95% CI) | SHR (95% CI) | SHR (95% CI) | SHR (95% CI) | SHR (95% CI) |
| Major cities | 1 | 1 | 1 | 1 | 1 | 1 |
| Inner regional | 0.99 (0.97–1.01) | 1.00 (0.98–1.02) | 1.01 (0.99–1.03) | 1.02 (1.00–1.04) | 1.01 (0.99–1.03) | 1.02 (1.00–1.04) |
| Outer regional/ Remote | 1.03 (1.00–1.06) | 1.04 (1.01–1.07) | 1.06 (1.03–1.09) | 1.07 (1.04–1.09) | 1.03 (1.01–1.06) | 1.03 (1.00–1.06) |
| SEIFA quintile | ||||||
| 1 (least disadvantaged) | 1 | 1 | 1 | 1 | 1 | 1 |
| 2 | 1.01 (0.99–1.04) | 1.01 (0.99–1.04) | 1.06 (1.04–1.09) | 1.04 (1.02–1.07) | 1.07 (1.04–1.10) | 1.07 (1.04–1.10) |
| 3 | 1.04 (1.02–1.07) | 1.03 (1.01–1.06) | 1.08 (1.05–1.10) | 1.06 (1.03–1.08) | 1.15 (1.12–1.18) | 1.14 (1.11–1.17) |
| 4 | 1.06 (1.04–1.09) | 1.05 (1.02–1.08) | 1.13 (1.11–1.16) | 1.11 (1.08–1.13) | 1.17 (1.14–1.20) | 1.17 (1.14–1.20) |
| 5 (most disadvantaged) | 1.08 (1.06–1.11) | 1.07 (1.04–1.10) | 1.17 (1.15–1.20) | 1.14 (1.12–1.17) | 1.25 (1.22–1.28) | 1.24 (1.21–1.27) |
| Country of birth | ||||||
| Australia | 1 | 1 | 1 | 1 | 1 | 1 |
| Other English speaking | 0.99 (0.97–1.01) | 0.99 (0.97–1.01) | 1.01 (0.99–1.03) | 1.00 (0.98–1.02) | 1.02 (1.00–1.05) | 1.00 (0.98–1.03) |
| Non-English speaking | 0.91 (0.89–0.94) | 0.91 (0.88–0.93) | 0.93 (0.92–0.95) | 0.92 (0.90–0.93) | 0.93 (0.91–0.95) | 0.90 (0.88–0.92) |
| Unknown | 0.37 (0.35–0.40) | 0.40 (0.37–0.43) | 0.16 (0.15–0.18) | 0.19 (0.17–0.20) | 0.17 (0.15–0.18) | 0.19 (0.17–0.20) |
SEIFA Socio-Economic Index for Areas, SHR Sub-hazard ratio, CI Confidence interval; Country of birth categorised into Australia, other English-speaking and non-English speaking countries and unknown
aModels adjusted for sex, age, cancer site and, as appropriate, for remoteness/SEIFA quintile/country of birth
bModels further adjusted for summary stage
Fig. 1Sub-hazard ratios for socio-economic disadvantage quintiles 2–5 compared with quintile 1 for cases diagnosed in 1980–1989, 1990–1999 and 2000–2008. Sub-hazard ratios with 95% confidence intervals. Socio-economic disadvantage measured as the Index of Relative Socio-Economic Disadvantage and categorised into quintiles (1: least disadvantaged – 5: most disadvantaged). Models adjusted for sex, age, remoteness, country of birth, cancer site, and summary stage
Cancer site-specific competing risk regression models of risk of cancer death by remoteness, socio-economic disadvantage and country of birth category, NSW 1980–2008
| Stomach | Colorectal | Liver | Lung | Melanoma | Breasta | Cervix | Prostate | |
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |
| Remoteness | SHR (95% CI)b | SHR (95% CI)b | SHR (95% CI)b | SHR (95% CI)b | SHR (95% CI)b | SHR (95% CI)b | SHR (95% CI)b | SHR (95% CI)b |
| Major cities | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Inner regional | 1.09 (1.04–1.14) | 1.02 (0.99–1.05) | 1.04 (0.95–1.13) | 1.02 (0.99–1.04) | 0.97 (0.92–1.03) | 1.00 (0.96–1.04) | 1.04 (0.93–1.16) | 1.08 (1.05–1.12) |
| Outer regional/Remote | 1.15 (1.07–1.24) | 1.12 (1.08–1.17) | 1.08 (0.95–1.24) | 1.02 (0.99–1.06) | 1.09 (1.00–1.19) | 1.04 (0.98–1.10) | 1.24 (1.07–1.43) | 1.10 (1.05–1.16) |
| SEIFA quintile | ||||||||
| 1 (least disadvantaged) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 2 | 0.99 (0.93–1.05) | 1.05 (1.01–1.08) | 1.01 (0.90–1.12) | 1.06 (1.02–1.09) | 1.10 (1.02–1.18) | 1.06 (1.01–1.11) | 0.94 (0.80–1.10) | 1.06 (1.01–1.11) |
| 3 | 1.01 (0.95–1.07) | 1.06 (1.02–1.10) | 1.07 (0.96–1.18) | 1.08 (1.05–1.12) | 1.13 (1.05–1.22) | 1.12 (1.07–1.18) | 1.10 (0.95–1.27) | 1.08 (1.03–1.13) |
| 4 | 1.03 (0.97–1.09) | 1.11 (1.07–1.14) | 1.11 (1.00–1.23) | 1.12 (1.09–1.15) | 1.12 (1.04–1.21) | 1.14 (1.09–1.19) | 1.13 (0.98–1.30) | 1.13 (1.08–1.19) |
| 5 (most disadvantaged) | 1.03 (0.97–1.09) | 1.14 (1.10–1.18) | 1.22 (1.11–1.34) | 1.15 (1.12–1.18) | 1.25 (1.16–1.34) | 1.14 (1.08–1.19) | 1.11 (0.97–1.27) | 1.16 (1.11–1.22) |
| Country of birth | ||||||||
| Australia | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Other English speaking | 1.00 (0.95–1.06) | 0.97 (0.93–1.00) | 0.89 (0.80–1.00) | 0.98 (0.95–1.00) | 0.94 (0.86–1.03) | 1.00 (0.95–1.04) | 0.83 (0.73–0.94) | 1.03 (0.99–1.08) |
| Non-English speaking | 0.87 (0.83–0.91) | 0.92 (0.89–0.95) | 0.84 (0.78–0.90) | 0.88 (0.86–0.90) | 1.26 (1.14–1.39) | 0.98 (0.94–1.02) | 0.82 (0.73–0.92) | 0.93 (0.89–0.97) |
| Unknown | 0.49 (0.41–0.58) | 0.32 (0.28–0.36) | 0.35 (0.25–0.50) | 0.48 (0.43–0.53) | 0.03 (0.03–0.04) | 0.27 (0.23–0.32) | 0.14 (0.09–0.22) | 0.13 (0.11–0.15) |
SEIFA Socio-Economic Index for Areas, SHR Sub-hazard ratio, CI Confidence interval; Country of birth categorised into Australia, other English-speaking and non-English speaking countries and unknown
aFemale breast cancers only
bModels adjusted for sex (when appropriate), age, diagnostic period, summary stage and, as appropriate, for remoteness/SEIFA quintile/country of birth